

Christopher R Flowers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6952683/publications.pdf>

Version: 2024-02-01

647
papers

26,253
citations

13068

68
h-index

8138

148
g-index

651
all docs

651
docs citations

651
times ranked

27816
citing authors

#	ARTICLE	IF	CITATIONS
1	A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 74-83.	0.6	4
2	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	0.8	34
3	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2867-2871.	2.5	24
4	PI3K β inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022, 139, 523-537.	0.6	56
5	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
6	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	13.9	278
7	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (≥ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
8	Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2022, 40, 1949-1957.	0.8	4
9	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	0.6	56
10	In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. <i>JCI Insight</i> , 2022, 7, .	2.3	9
11	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , the, 2022, 9, e289-e300.	2.2	24
12	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	0.6	8
13	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1103-1110.	1.1	4
14	Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. <i>American Journal of Hematology</i> , 2022, 97, 1044-1054.	2.0	8
15	The impact of sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
16	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. <i>British Journal of Haematology</i> , 2021, 192, e38-e42.	1.2	33
17	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	0.6	4
18	Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 1077-1087.	0.6	13

#	ARTICLE	IF	CITATIONS
19	Perceptions of clinical care and research among African-American patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1860-1868.	0.6	1
20	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	2.0	6
21	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3272-3276.	0.6	95
22	Understanding and Addressing Disparities in Patients With Hematologic Malignancies: Approaches for Clinicians. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 351-357.	1.8	2
23	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	2.5	4
24	The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. <i>Blood</i> , 2021, 138, 785-789.	0.6	9
25	Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab198.	0.4	7
26	Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7534-7534.	0.8	4
27	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
28	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. <i>Nature Communications</i> , 2021, 12, 2877.	5.8	35
29	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	0.6	5
30	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
31	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	2.0	6
32	Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study. <i>Haematologica</i> , 2021, 106, 2774-2778.	1.7	12
33	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	2.5	57
34	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
35	Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing. <i>ACS Sensors</i> , 2021, 6, 3789-3799.	4.0	8
36	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21

#	ARTICLE	IF	CITATIONS
37	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.4	6
38	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
39	Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 2.	2.8	29
40	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2021, 138, 2463-2463.	0.6	0
41	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 4536-4536.	0.6	0
42	Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. <i>Blood</i> , 2021, 138, 3572-3572.	0.6	2
43	Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool. <i>Blood</i> , 2021, 138, 1922-1922.	0.6	0
44	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3526-3526.	0.6	0
45	Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 1448-1448.	0.6	0
46	Axicabtagene CiloleuceL in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. <i>Blood</i> , 2021, 138, 1740-1740.	0.6	2
47	Realmind: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 5010-5010.	0.6	0
48	Sirp± and CSF1R Positive Tissue Macrophages Are Increased in Patients with Follicular Lymphoma Who Relapse after Frontline Lenalidomide and Rituximab. <i>Blood</i> , 2021, 138, 1336-1336.	0.6	0
49	A Phase 1/1b Open-Label, Multicenter, Two-Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1679-1679.	0.6	0
50	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	0.6	1
51	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	0.6	0
52	Connect Â® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study. <i>Blood</i> , 2021, 138, 1460-1460.	0.6	0
53	Immune-Depleted Tumor Microenvironment Signature Is Associated with BTK Inhibitor Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 1321-1321.	0.6	0
54	Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1408-1408.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3525-3525.	0.6	8
56	Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 3870-3870.	0.6	0
57	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	0.8	971
58	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	0.8	488
59	Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 234-243.e10.	0.2	0
60	Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia. <i>Leukemia and Lymphoma</i> , 2020, 61, 896-904.	0.6	2
61	Retroperitoneal Follicular Dendritic Cell Sarcoma: A Case Report. <i>Advances in Radiation Oncology</i> , 2020, 5, 297-300.	0.6	1
62	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
63	Priorities for Rural Lymphoma Survivors: A Qualitative Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 47-52.e3.	0.2	9
64	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity score-matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	1.2	7
65	Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. <i>JCO Global Oncology</i> , 2020, 6, 1124-1133.	0.8	7
66	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 321-346.	157.7	481
67	Stiffness based enrichment of leukemia cells using microfluidics. <i>APL Bioengineering</i> , 2020, 4, 036101.	3.3	7
68	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect A® CLL Registry. <i>EJHaem</i> , 2020, 1, 188-198.	0.4	2
69	Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 757-767.e3.	0.2	5
70	Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1844-1855.	1.1	10
71	Prognostic Value of Disease Location in Secondary Central Nervous System Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e751-e752.	0.4	0
72	How Much Did We Impact the Risk of Second Malignancies in Patients with Classical Hodgkin Lymphoma by Changing the Treatment Paradigm?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S141-S142.	0.4	0

#	ARTICLE	IF	CITATIONS
73	How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. <i>Leukemia and Lymphoma</i> , 2020, 61, 3283-3286.	0.6	0
74	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	2.5	67
75	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935.	2.8	8
76	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2020, 126, 3493-3503.	2.0	15
77	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. <i>Lancet Haematology</i> , 2020, 7, e490-e497.	2.2	14
78	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	0.6	158
79	Lenalidomide in follicular lymphoma. <i>Blood</i> , 2020, 135, 2133-2136.	0.6	21
80	SARS-CoV-2 in multiple myeloma: initial observation and management. <i>Leukemia and Lymphoma</i> , 2020, 61, 2763-2766.	0.6	2
81	Impact of maintenance rituximab in patients with <i>de novo</i> transformed indolent B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2985-2989.	0.6	2
82	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	2.5	134
83	A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1555-1564.	0.6	1
84	Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia. <i>Cancer</i> , 2020, 126, 1700-1707.	2.0	15
85	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. <i>Leukemia and Lymphoma</i> , 2020, 61, 1380-1387.	0.6	4
86	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	2.0	54
87	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Advances</i> , 2020, 4, 1407-1418.	2.5	12
88	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.2	2
89	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	2.5	43
90	Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	13

#	ARTICLE	IF	CITATIONS
91	Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. <i>Blood</i> , 2020, 136, 17-19.	0.6	17
92	Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 41-42.	0.6	3
93	Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≥ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. <i>Blood</i> , 2020, 136, 35-36.	0.6	4
94	Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	0.6	2
95	A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). <i>Blood</i> , 2020, 136, 40-41.	0.6	15
96	Abstract B092: Epstein-Barr virus prevalence in classical Hodgkin lymphoma tumors by race/ethnicity in a multiethnic U.S. population. , 2020, , .		0
97	Abstract 2049: Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma. <i>Cancer Research</i> , 2020, 80, 2049-2049.	0.4	2
98	Modernizing Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma: Consensus Recommendations Using a Modified Delphi-Method Survey. <i>Blood</i> , 2020, 136, 49-50.	0.6	0
99	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
100	Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
101	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18.	0.6	1
102	Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. <i>Blood</i> , 2020, 136, 9-11.	0.6	1
103	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-39.	0.6	0
104	Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
105	Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer. <i>Oncology</i> , 2020, 34, 494-499.	0.4	2
106	Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
107	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-35.	0.6	1
108	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020, 136, 10-12.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
110	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
111	Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. <i>Blood</i> , 2020, 136, 32-33.	0.6	2
112	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
113	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
114	Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials. <i>Oncology</i> , 2020, 34, 216-223.	0.4	3
115	Patient and caregiver perceptions of lymphoma care and research opportunities: A qualitative study. <i>Cancer</i> , 2019, 125, 4096-4104.	2.0	12
116	Insurance status impacts overall survival in Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3225-3234.	0.6	10
117	Cost burden of diffuse large B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 645-661.	0.7	14
118	Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 699-708.e5.	0.2	4
119	Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. <i>Leukemia and Lymphoma</i> , 2019, 60, 2356-2364.	0.6	2
120	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 959-973.	1.0	18
121	The whole-genome landscape of Burkitt lymphoma subtypes. <i>Blood</i> , 2019, 134, 1598-1607.	0.6	113
122	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1811-1820.	0.6	75
123	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <i>Lancet Haematology</i> , 2019, 6, e100-e109.	2.2	65
124	A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. <i>Cancer</i> , 2019, 125, 1837-1847.	2.0	12
125	Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 300-309.e5.	0.2	5
126	PET-derived tumor metrics predict DLBCL response and progression-free survival. <i>Leukemia and Lymphoma</i> , 2019, 60, 1965-1971.	0.6	17

#	ARTICLE	IF	CITATIONS
127	Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. <i>Clinical Cancer Research</i> , 2019, 25, 6283-6294.	3.2	38
128	Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e312-e320.	0.2	13
129	Reply to M.A. Slavin et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1140-1141.	0.8	3
130	Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2255-2263.	0.6	0
131	Clinical Implications of Febrile Neutropenia Guidelines in the Cancer Patient Population. <i>Journal of Oncology Practice</i> , 2019, 15, 25-26.	2.5	7
132	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-527.	0.8	0
133	Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S23-S24.	2.0	0
134	Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. <i>International Journal of Cancer</i> , 2019, 145, 2647-2660.	2.3	36
135	POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL. <i>Hematological Oncology</i> , 2019, 37, 68-70.	0.8	4
136	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 418-427.	1.0	8
137	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019, 125, 185-193.	2.0	4
138	Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 89-94.	0.2	1
139	Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1656-1667.	0.6	14
140	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
141	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019, 60, 894-903.	0.6	18
142	Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	1.2	51
143	Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 239-243.	0.2	4
144	Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL). <i>Blood</i> , 2019, 134, 5252-5252.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	0.6	10
146	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019, 134, 400-400.	0.6	2
147	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019, 134, 1610-1610.	0.6	3
148	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9
149	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	0.6	1
150	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	0.6	1
151	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	0.6	10
152	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	0.6	9
153	Association of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia with environmental exposure to benzene and trichloroethylene.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1551-1551.	0.8	3
154	Impact on survival of surveillance imaging after first remission in follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7536-7536.	0.8	2
155	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7544-7544.	0.8	3
156	Autograft vs Allograft Comparison in Pediatric Medial Patellofemoral Ligament Reconstruction. <i>Ochsner Journal</i> , 2019, 19, 96-101.	0.5	23
157	Exploring the Needs and Priorities of Black Patients with Lymphoma: A Qualitative Study. <i>Blood</i> , 2019, 134, 5815-5815.	0.6	0
158	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	0.6	0
159	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. <i>Blood</i> , 2019, 134, 2812-2812.	0.6	0
160	Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 410-410.	0.6	0
161	Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab. <i>Blood</i> , 2019, 134, 4008-4008.	0.6	0
162	Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 414-414.	0.6	0

#	ARTICLE	IF	CITATIONS
163	A Data-Driven Approach to Define Parsimonious Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 3416-3416.	0.6	2
164	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. <i>Blood</i> , 2019, 134, 19-19.	0.6	4
165	Abstract 4206: Examining genetic ancestry in diffuse large B-cell lymphoma (DLBCL). , 2019, , .		0
166	Abstract 5053: Epstein-Barr virus prevalence in classical Hodgkin lymphoma tumors is explained by histologic subtype, not race/ethnicity in a multiethnic US population. , 2019, , .		0
167	Ethnic disparity in primary cutaneous <sc>CD</sc>30⁺ Tâ€cell lymphoproliferative disorders: an analysis of 1496 cases from the <sc>US</sc> National Cancer database. <i>British Journal of Haematology</i> , 2018, 181, 721-722.	1.2	0
168	Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. <i>Cancer Causes and Control</i> , 2018, 29, 551-561.	0.8	38
169	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	2.0	40
170	Impact of the posttransplant lymphoproliferative disorder subtype on survival. <i>Cancer</i> , 2018, 124, 2327-2336.	2.0	20
171	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect^ÂCLL cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 2327-2335.	0.6	5
172	Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEERâ€Medicare Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e115-e121.	0.2	10
173	Effective management strategies for patients with marginal zone lymphoma. <i>Future Oncology</i> , 2018, 14, 1213-1222.	1.1	11
174	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 114-124.e2.	0.2	23
175	Balancing patient value and payer cost in hematologic malignancies: can it be done?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 123-126.	0.7	1
176	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	0.6	28
177	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5
178	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
179	Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. <i>Leukemia and Lymphoma</i> , 2018, 59, 888-895.	0.6	11
180	Reply to J.A. Talcott. <i>Journal of Clinical Oncology</i> , 2018, 36, 3174-3175.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Microsimulation Modeling in Oncology. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	1.0	16
182	Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	1.0	2
183	Consolidative Radiation Therapy (RT) for Advanced Stage Hodgkin's Lymphoma (HL) May Improve Progression Free Survival Than ABVD Alone for Adult Patients.. International Journal of Radiation Oncology Biology Physics, 2018, 102, e280.	0.4	0
184	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology, 2018, 36, 2593-2602.	0.8	59
185	Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2018, 14, 250-255.	2.5	24
186	What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?. Journal of Clinical Oncology, 2018, 36, 3183-3185.	0.8	8
187	Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 1443-1453.	0.8	248
188	Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 3043-3054.	0.8	357
189	Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2018, 14, 692-695.	2.5	23
190	Identifying and Addressing Disparities in Survival Outcomes for Rural Patients With Cancer. JAMA Network Open, 2018, 1, e181243.	2.8	15
191	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. International Journal of Molecular Sciences, 2018, 19, 4118.	1.8	7
192	Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT). Biology of Blood and Marrow Transplantation, 2018, 24, S137-S138.	2.0	0
193	The association of physical activity before and after lymphoma diagnosis with survival outcomes. American Journal of Hematology, 2018, 93, 1543-1550.	2.0	16
194	Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology American Society of Hematology Education Program, 2018, 2018, 185-188.	0.9	7
195	Sequencing of therapies in relapsed follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 189-193.	0.9	9
196	Novel immunotherapy approaches to follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 194-199.	0.9	8
197	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K inhibitors and VIP antagonists. Blood Advances, 2018, 2, 210-223.	2.5	87
198	Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. Ca-A Cancer Journal for Clinicians, 2018, 68, 250-281.	157.7	1,287

#	ARTICLE	IF	CITATIONS
199	Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opinion on Investigational Drugs, 2018, 27, 513-522.	1.9	46
200	Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of Oncology, 2018, 29, 1932-1938.	0.6	63
201	Disparities in survival by insurance status in follicular lymphoma. Blood, 2018, 132, 1159-1166.	0.6	24
202	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	2.8	26
203	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096.	0.4	34
204	Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. British Journal of Haematology, 2018, 183, 385-399.	1.2	24
205	A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 569-575.e1.	0.2	30
206	The need to assess financial adverse events. Lancet Haematology, the, 2018, 5, e508-e509.	2.2	1
207	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals of Oncology, 2018, 29, 1822-1827.	0.6	61
208	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2862-2870.	0.6	13
209	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. Blood, 2018, 132, 1702-1702.	0.6	6
210	Survivor and Caregiver Perceptions of Lymphoma: A Qualitative Study. Blood, 2018, 132, 3561-3561.	0.6	1
211	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. Blood, 2018, 132, 2892-2892.	0.6	4
212	Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF- κ B Pathway. Blood, 2018, 132, 1565-1565.	0.6	5
213	Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. Blood, 2018, 132, 1683-1683.	0.6	18
214	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. Blood, 2018, 132, 2157-2157.	0.6	1
215	Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Blood, 2018, 132, 4197-4197.	0.6	1
216	Using Informatics Tools to Characterize Precision Medicine Treatments for Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 4801-4801.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. Journal of Clinical Oncology, 2018, 36, 10042-10042.	0.8	1
218	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.. Journal of Clinical Oncology, 2018, 36, 7507-7507.	0.8	45
219	Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2018, 36, 7547-7547.	0.8	11
220	Association of insurance status and race with overall survival among patients with cutaneous T-cell lymphoma: A National Cancer DataBase analysis.. Journal of Clinical Oncology, 2018, 36, e18624-e18624.	0.8	3
221	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).. Journal of Clinical Oncology, 2018, 36, TPS7589-TPS7589.	0.8	3
222	Effect of physical activity (PA) before and after diagnosis on overall survival (OS) for patients (pts) with lymphoma.. Journal of Clinical Oncology, 2018, 36, 95-95.	0.8	0
223	Racial and socioeconomic disparities in mantle cell lymphoma.. Journal of Clinical Oncology, 2018, 36, e18610-e18610.	0.8	0
224	A meta-analysis on ABVD administration in HIV+ patients with advanced stage Hodgkin's lymphoma (HL).. Journal of Clinical Oncology, 2018, 36, e19522-e19522.	0.8	0
225	ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.. Journal of Clinical Oncology, 2018, 36, TPS7587-TPS7587.	0.8	0
226	Outcomes in non-Hodgkin lymphoma by Latino country-of-origin (COO).. Journal of Clinical Oncology, 2018, 36, e18727-e18727.	0.8	0
227	Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2018, 36, e19509-e19509.	0.8	0
228	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 4153-4153.	0.6	0
229	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. Blood, 2018, 132, 5911-5911.	0.6	1
230	Evaluation of Maintenance Therapy in Cutaneous T-Cell Lymphoma Patients Receiving Total Skin Electron Beam Radiation Therapy. Blood, 2018, 132, 1639-1639.	0.6	0
231	Circulating B Cell Subsets from Untreated Diffuse Large B Cell Lymphoma (DLBCL) Patients Resemble Those of Patients with Autoimmune Disease. Blood, 2018, 132, 4221-4221.	0.6	0
232	Characterization of Clinical Features and Survival of Patients with Autoimmune-Associated Diffuse Large B Cell Lymphoma in a Large Institutional Cohort. Blood, 2018, 132, 4233-4233.	0.6	0
233	Increased Charlson Comorbidity Index (CCI) Is Not Associated with Inferior Clinical Outcomes in Patients with Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 5327-5327.	0.6	0
234	Utilization of a Novel Method of Detection of CD30 Expression in Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 2978-2978.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Influenza Vaccination Rates during the First Year after Diagnosis of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2018, 132, 4820-4820.	0.6	0
236	Priorities for Rural Lymphoma Survivors: An Exploratory Study. <i>Blood</i> , 2018, 132, 4789-4789.	0.6	0
237	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
238	Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 271-279.	1.1	48
239	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	7.7	163
240	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	0.8	89
241	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	0.8	87
242	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	0.6	243
243	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
244	Unmet needs in the first-line treatment of follicular lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2094-2106.	0.6	31
245	Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?. <i>Cancer</i> , 2017, 123, 3222-3225.	2.0	10
246	Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. <i>British Journal of Haematology</i> , 2017, 178, 72-80.	1.2	38
247	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. <i>Oncogene</i> , 2017, 36, 4224-4232.	2.6	17
248	Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S265-S266.	2.0	1
249	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	0.6	68
250	Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 651-657.	1.0	10
251	Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. <i>BMC Cancer</i> , 2017, 17, 198.	1.1	9
252	A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2268-2269.	0.6	4

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	1.7	68
254	Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 561-564.	0.6	29
255	Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S377.	0.2	0
256	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	13.5	804
257	Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2017, 130, 2180-2185.	0.6	35
258	Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 353-361.	157.7	49
259	MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017, 123, 4411-4418.	2.0	23
260	The importance of immunization in cancer prevention, treatment, and survivorship. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 398-410.	157.7	34
261	Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Cancer Research</i> , 2017, 77, 4548-4555.	0.4	52
262	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017, 22, 1415-1418.	1.9	7
263	Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. <i>Oncologist</i> , 2017, 22, 694-699.	1.9	27
264	Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1570-1580.	0.6	8
265	HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 303-311.	1.1	49
266	[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 809-815.	0.6	8
267	Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. <i>Bone Marrow Transplantation</i> , 2017, 52, 132-134.	1.3	1
268	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	2.0	56
269	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 2433-2443.	2.5	12
270	Making the Case for Improving Oncology Workforce Diversity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 18-22.	1.8	20

#	ARTICLE	IF	CITATIONS
271	Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2017, 35, 3075-3082.	0.8	62
272	Reply to C. Nabhan et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1864-1865.	0.8	1
273	Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Nonâ€œGerminal Center B-Cellâ€œLike Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3538-3546.	0.8	151
274	American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. <i>Journal of Clinical Oncology</i> , 2017, 35, 2576-2579.	0.8	41
275	Reply to Ã• Benedict et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 3086-3087.	0.8	1
276	When to Choose Transplant in Follicular Lymphoma: Navigating a Complex Landscape. <i>Journal of Oncology Practice</i> , 2017, 13, 808-809.	2.5	1
277	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	0.6	12
278	Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation. <i>Annals of Lymphoma</i> , 2017, 1, 1-1.	4.5	14
279	Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7511-7511.	0.8	4
280	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7537-7537.	0.8	2
281	Making the Case for Improving Oncology Workforce Diversity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 18-22.	1.8	9
282	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7541-7541.	0.8	0
283	Interim metabolic tumor volume to predict response in diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7557-7557.	0.8	0
284	A multistate model for follicular lymphoma (FL) patients (pts) who experience early progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18164-e18164.	0.8	0
285	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017, 130, 914-914.	0.6	2
286	Insurance Status Impacts Survival in Burkitt Lymphoma. <i>Blood</i> , 2017, 130, 916-916.	0.6	0
287	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016, 06, .	0.3	3
288	Breast Cancer Screening for Women at Average Risk. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 153-155.	0.2	1

#	ARTICLE	IF	CITATIONS
289	Outcomes following watchful waiting for stage I-II follicular lymphoma patients in the modern era. <i>British Journal of Haematology</i> , 2016, 172, 724-734.	1.2	44
290	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. <i>Immunotherapy</i> , 2016, 8, 1335-1346.	1.0	9
291	GIFT4 fusokine converts leukemic B cells into immune helper cells. <i>Journal of Translational Medicine</i> , 2016, 14, 106.	1.8	9
292	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	1.2	20
293	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
294	CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation. <i>Dermatology and Therapy</i> , 2016, 6, 251-263.	1.4	4
295	B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. <i>Expert Review of Hematology</i> , 2016, 9, 553-561.	1.0	8
296	Validation of cutaneous lymphoma international prognostic index (CLUPI) for mycosis fungoides and Sézary syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 2813-2819.	0.6	16
297	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
298	Identifying risk factors for B-cell lymphoma. <i>Blood</i> , 2016, 127, 10-11.	0.6	9
299	Validation of Cutaneous Lymphoma International Prognostic Index (CLUPI) for Mycosis Fungoides and Sezary Syndrome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S165-S166.	0.4	0
300	Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 304-305.	0.7	4
301	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 443-459.	157.7	791
302	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , 2016, 175, 892-903.	1.2	42
303	ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 384-395.	0.6	3
304	ACR Appropriateness Criteria® Hodgkin Lymphoma—Favorable Prognosis Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 535-544.	0.6	4
305	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	2.0	22
306	Resolving uncertainty in the spatial relationships between passive benzene exposure and risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology</i> , 2016, 41, 139-151.	0.8	12

#	ARTICLE	IF	CITATIONS
307	Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S200-S201.	2.0	0
308	Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 264-273.	1.1	71
309	Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. <i>Cancer</i> , 2016, 122, 2356-2363.	2.0	51
310	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. <i>Clinical Colorectal Cancer</i> , 2016, 15, 1-6.	1.0	72
311	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	1.4	52
312	The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2016, 57, 1876-1882.	0.6	11
313	Perspectives in Oncology Drug Pricing—Reply. <i>JAMA Oncology</i> , 2016, 2, 402.	3.4	0
314	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016, 54, 11-17.	1.3	63
315	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	0.6	7
316	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. <i>Blood</i> , 2016, 128, 1087-1087.	0.6	4
317	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016, 128, 1102-1102.	0.6	3
318	Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2016, 128, 1213-1213.	0.6	9
319	a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2016, 128, 1776-1776.	0.6	3
320	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	0.6	3
321	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	0.6	5
322	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196.	0.6	1
323	Distress and Perceived Impact on Well-Being for Low- or Intermediate-Risk and High-Risk Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 5970-5970.	0.6	2
324	Long-term follow-up of the PI3K γ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. <i>Journal of Clinical Oncology</i> , 2016, 34, 7512-7512.	0.8	12

#	ARTICLE	IF	CITATIONS
325	Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era.. Journal of Clinical Oncology, 2016, 34, 7543-7543.	0.8	2
326	Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.. Journal of Clinical Oncology, 2016, 34, 7565-7565.	0.8	2
327	Deferred treatment as a viable option for selected patients with mantle cell lymphoma.. Journal of Clinical Oncology, 2016, 34, 7567-7567.	0.8	1
328	Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. Southern Medical Journal, 2016, 109, 606-614.	0.3	13
329	Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.. Journal of Clinical Oncology, 2016, 34, 6518-6518.	0.8	0
330	Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.. Journal of Clinical Oncology, 2016, 34, 6607-6607.	0.8	0
331	Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2016, 128, 5408-5408.	0.6	0
332	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. Blood, 2016, 128, 513-513.	0.6	0
333	Use of Metabolic Tumor Volume (MTV) in Patients with Mantle Cell Lymphoma. Blood, 2016, 128, 5321-5321.	0.6	0
334	Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the ConnectA® CLL Registry. Blood, 2016, 128, 3581-3581.	0.6	0
335	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the ConnectA® CLL Registry. Blood, 2016, 128, 5941-5941.	0.6	0
336	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. Blood, 2016, 128, 103-103.	0.6	0
337	Sociodemographic Factors Predict Medical Conditions Among Five-Year Survivors of Adolescent and Young Adult Hodgkin Lymphoma. Blood, 2016, 128, 693-693.	0.6	0
338	CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4225-4225.	0.6	0
339	Characterizing Autoimmune Disease-Associated Diffuse Large B Cell Lymphoma in a SEER-Medicare Cohort. Blood, 2016, 128, 4214-4214.	0.6	0
340	An Evaluation of the Role of Surveillance Imaging in Mantle Cell Lymphoma in First Remission. Blood, 2016, 128, 1799-1799.	0.6	0
341	Prolonged Progression-Free Survival Is Possible in Patients with Diffuse Large B-Cell Lymphoma Receiving > 1 Salvage Therapies before Autologous Stem Cell Transplant. Blood, 2016, 128, 5825-5825.	0.6	1
342	Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies. Discovery Medicine, 2016, 21, 181-8.	0.5	9

#	ARTICLE	IF	CITATIONS
343	ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. <i>Oncology</i> , 2016, 30, 1099-103, 1106-8.	0.4	2
344	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	0.6	161
345	Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. <i>BMJ Open</i> , 2015, 5, e008350.	0.8	8
346	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12
347	Reply to age-related differences in quality of life among patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 2858-2859.	2.0	3
348	Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 3748-3748.	2.0	0
349	Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. <i>British Journal of Haematology</i> , 2015, 170, 85-95.	1.2	50
350	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	0.6	9
351	Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. <i>Cancer</i> , 2015, 121, 3387-3389.	2.0	1
352	Plerixafor in combination with granulocyte colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015, 55, 2351-2357.	0.8	6
353	Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma Using a Modern Dual-Field Rotational Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 183-191.	0.4	36
354	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3842-3843.	0.8	0
355	Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2015, 56, 557-558.	0.6	4
356	Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 1800-1808.	2.0	54
357	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. <i>American Journal of Epidemiology</i> , 2015, 181, 406-421.	1.6	54
358	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118.	0.8	144
359	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656.	0.8	911
360	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	0.8	97

#	ARTICLE	IF	CITATIONS
361	Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era. <i>Acta Haematologica</i> , 2015, 134, 109-110.	0.7	2
362	Predictors of Local Recurrence After Rituximab-Based Chemotherapy Alone in Stage III and IV Diffuse Large B-Cell Lymphoma: Guiding Decisions for Consolidative Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 107-112.	0.4	24
363	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
364	Next-generation surveillance strategies for patients with lymphoma. <i>Future Oncology</i> , 2015, 11, 1977-1991.	1.1	15
365	Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. <i>Value in Health</i> , 2015, 18, 189-197.	0.1	30
366	New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 531-544.	1.1	66
367	Efficacy and Tolerability of Anthracycline-Based Therapy in Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 270-277.	0.2	10
368	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 514-518.	0.2	4
369	Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. <i>Annals of Oncology</i> , 2015, 26, 2311-2317.	0.6	22
370	Breast Cancer Screening for Women at Average Risk. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1599.	3.8	1,283
371	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8
372	To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 244-255.	1.2	15
373	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	3.4	43
374	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732.	0.8	86
375	A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 694-698.	0.2	1
376	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. <i>Leukemia and Lymphoma</i> , 2015, 56, 1295-1302.	0.6	22
377	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 383-389.	0.6	7
378	A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 1496-1496.	0.6	1

#	ARTICLE	IF	CITATIONS
379	Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. <i>Blood</i> , 2015, 126, 1538-1538.	0.6	6
380	A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 255-255.	0.6	31
381	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	0.6	8
382	Cost-Effectiveness of Subtype-Based Treatment Strategies for Diffuse Large B-Cell Lymphoma Patients (DLBCL). <i>Blood</i> , 2015, 126, 4476-4476.	0.6	2
383	Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918). <i>Blood</i> , 2015, 126, 811-811.	0.6	30
384	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6613-6613.	0.8	1
385	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7013-7013.	0.8	2
386	Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8501-8501.	0.8	6
387	Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8532-8532.	0.8	3
388	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 368-368.	0.8	1
389	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 658-658.	0.8	1
390	Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8535-8535.	0.8	0
391	Necitumumab in metastatic squamous non-small cell lung cancer (mSqNSCLC): Establishing a value-based cost.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6505-6505.	0.8	1
392	Impact of racial residential segregation (RRS) on stage at diagnosis and survival after diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6557-6557.	0.8	0
393	Abstract A11: GIFT4-reprogrammed leukemic B cells for CLL immunotherapy.. , 2015, , .		0
394	Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 5095-5095.	0.6	0
395	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study. <i>Blood</i> , 2015, 126, 3284-3284.	0.6	0
396	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry. <i>Blood</i> , 2015, 126, 4483-4483.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015, 126, 4527-4527.	0.6	0
398	Deferred Treatment Is Associated with Improved Overall Survival in Patients with Newly Diagnosed Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 2717-2717.	0.6	0
399	Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma. <i>Blood</i> , 2015, 126, 5043-5043.	0.6	0
400	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL [®] Registry. <i>Blood</i> , 2015, 126, 5270-5270.	0.6	0
401	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	0.9	98
402	Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. <i>Bone Marrow Transplantation</i> , 2014, 49, 185-189.	1.3	18
403	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 26-40.	0.9	151
404	Optimal disease surveillance strategies in non-Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 481-487.	0.9	12
405	Insurance status is related to diffuse large B-cell lymphoma survival. <i>Cancer</i> , 2014, 120, 1220-1227.	2.0	47
406	ACR appropriateness Criteria [®] pediatric Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1305-1312.	0.8	16
407	The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. <i>Cancer</i> , 2014, 120, 1830-1837.	2.0	33
408	Putting the [~] Activate [™] in Activated B Cell-like Diffuse Large B Cell Lymphoma: A Role for the Noncanonical NF- κ B Pathway. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S143.	0.2	0
409	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014, 25, 2211-2217.	0.6	126
410	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 66-75.	0.9	52
411	PI3K ^γ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	13.9	956
412	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	0.9	16
413	Dermato-Neuro Syndrome in a Patient Treated With Autologous Stem Cell Transplant for Scleromyxedema. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e213-e215.	0.2	11
414	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	1.0	35

#	ARTICLE	IF	CITATIONS
415	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
416	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
417	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.2	86
418	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 76-86.	0.9	31
419	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 852-857.	2.0	29
420	Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S162.	2.0	3
421	Simplified Technique for Administration of High Dose Melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S291-S292.	2.0	0
422	Socioeconomic disparities in lymphoma. <i>Blood</i> , 2014, 123, 3530-3531.	0.6	25
423	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
424	Abstract LB-272: Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma. <i>Cancer Research</i> , 2014, 74, LB-272-LB-272.	0.4	4
425	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014, 124, 1708-1708.	0.6	10
426	The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 1722-1722.	0.6	10
427	A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 1725-1725.	0.6	2
428	Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study. <i>Blood</i> , 2014, 124, 3044-3044.	0.6	1
429	Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect [®] CLL Registry. <i>Blood</i> , 2014, 124, 3338-3338.	0.6	2
430	Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6527-6527.	0.8	2
431	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19554-e19554.	0.8	3
432	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. <i>Southern Medical Journal</i> , 2014, 107, 497-500.	0.3	3

#	ARTICLE	IF	CITATIONS
433	Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 6502-6502.	0.8	0
434	Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients (pts).. Journal of Clinical Oncology, 2014, 32, 8550-8550.	0.8	0
435	Characteristics, treatments, and survival outcome of mantle cell lymphoma in women: A single center analysis.. Journal of Clinical Oncology, 2014, 32, e19559-e19559.	0.8	0
436	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. Journal of Clinical Oncology, 2014, 32, e19561-e19561.	0.8	0
437	Rituximab Administration before Allogeneic HSCT Is Associated with Accelerated T Cell Reconstitution after Transplantation: Kinetic Evidence for a Graft-Versus-Leukemia Effect. Blood, 2014, 124, 3905-3905.	0.6	7
438	A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin's Lymphoma. Blood, 2014, 124, 4432-4432.	0.6	0
439	Disease Characteristics, Patterns of Care, and Survival in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4480-4480.	0.6	0
440	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 864-864.	0.6	1
441	Insurance Status Impacts Survival in Follicular Lymphoma. Blood, 2014, 124, 1327-1327.	0.6	0
442	Determinants and Outcomes of the Use of Positron Emission Tomography (PET)-Staging in Newly Diagnosed Follicular Lymphoma (FL). Blood, 2014, 124, 2600-2600.	0.6	0
443	Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. Blood, 2014, 124, 4672-4672.	0.6	0
444	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion, 2013, 53, 76-84.	0.8	4
445	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Supportive Care in Cancer, 2013, 21, 2853-2860.	1.0	26
446	American Cancer Society lung cancer screening guidelines. Ca-A Cancer Journal for Clinicians, 2013, 63, 106-117.	157.7	611
447	Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells. Biology of Blood and Marrow Transplantation, 2013, 19, S191.	2.0	0
448	Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 657-663.	0.2	12
449	Bortezomib-containing induction regimens in transplant-eligible myeloma patients. Cancer, 2013, 119, 4119-4128.	2.0	36
450	Using primary site as a predictor of survival in mantle cell lymphoma. Cancer, 2013, 119, 1570-1577.	2.0	33

#	ARTICLE	IF	CITATIONS
451	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. <i>Cancer</i> , 2013, 119, 4129-4136.	2.0	18
452	Racial differences in chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 3593-3595.	2.0	11
453	Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Results in Fewer Plasmacytoid Dendritic Cells in the Graft and Enhanced Donor T Cell Engraftment with Th1 Polarization: Results from a Randomized Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 460-467.	2.0	19
454	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 2189-2204.	0.8	717
455	Patterns of Failure in Advanced Stage Diffuse Large B-Cell Lymphoma Patients After Complete Response to R-CHOP Immunochemotherapy and the Emerging Role of Consolidative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 569-577.	0.4	76
456	Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1393-1395.	2.0	18
457	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2122-2130.	0.6	16
458	Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. <i>Leukemia and Lymphoma</i> , 2013, 54, 752-759.	0.6	98
459	Examining racial differences in diffuse large B-cell lymphoma presentation and survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 268-276.	0.6	50
460	Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. <i>Annals of Oncology</i> , 2013, 24, 441-448.	0.6	79
461	Communicating Safe Outpatient Management of Fever and Neutropenia. <i>Journal of Oncology Practice</i> , 2013, 9, 207-210.	2.5	10
462	Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 3309-3317.	2.0	25
463	Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4132-4139.	0.8	93
464	The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1089-1108.	1.1	0
465	Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 794-810.	0.8	364
466	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1398-1403.	3.3	494
467	Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). <i>Blood</i> , 2013, 122, 1820-1820.	0.6	15
468	Racial Disparities In Prediction Of 5-Year Overall Survival For Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2013, 122, 2922-2922.	0.6	1

#	ARTICLE	IF	CITATIONS
469	Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma. <i>Blood</i> , 2013, 122, 2923-2923.	0.6	2
470	PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 4245-4245.	0.6	1
471	Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 510-510.	0.6	5
472	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013, 122, 85-85.	0.6	10
473	Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8609-8609.	0.8	1
474	Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8559-8559.	0.8	0
475	Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7035-7035.	0.8	0
476	Patterns of failure in advanced-stage diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP chemotherapy and the emerging role of consolidative radiotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8546-8546.	0.8	0
477	Spatial Epidemiology Of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma In The State Of Georgia. <i>Blood</i> , 2013, 122, 1683-1683.	0.6	0
478	Patterns Of Care and Outcomes Of Anthracyclines In Grade 3 Follicular Lymphoma (FL). <i>Blood</i> , 2013, 122, 4401-4401.	0.6	0
479	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013, 122, 768-768.	0.6	0
480	Relationship Between Residential Proximity To Environmental Protection Agency (EPA) Designated Toxic Release Sites and The Risk Of Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 1684-1684.	0.6	0
481	Patterns and Outcomes Of First-Line Management Strategies In Older Adults With Low-Grade Follicular Lymphoma (FL). <i>Blood</i> , 2013, 122, 1805-1805.	0.6	0
482	Exome Sequencing Of African American Siblings With Activated, B-Cell Like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 3014-3014.	0.6	0
483	Patterns Of First-Line Management Strategies In Older Adults With Follicular Lymphoma (FL). <i>Blood</i> , 2013, 122, 2983-2983.	0.6	0
484	Disease Characteristics, Patterns Of Care, and Outcomes Of Follicular Lymphoma (FL) In The Oldest Old. <i>Blood</i> , 2013, 122, 1817-1817.	0.6	0
485	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. <i>Blood</i> , 2013, 122, 3058-3058.	0.6	0
486	Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 842-842.	0.6	18

#	ARTICLE	IF	CITATIONS
487	Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin Lymphoma - a commentary on report from Krull and colleagues. <i>Translational Pediatrics</i> , 2013, 2, 1-2.	0.5	1
488	ACR Appropriateness Criteria: Localized nodal indolent lymphoma. <i>Oncology</i> , 2013, 27, 786-94.	0.4	4
489	Initial management strategies for follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 35-45.	0.7	10
490	Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1520-1530.	1.1	76
491	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, 2012, 87.	1.2	17
492	Exploring Risk Factors for Follicular Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-13.	0.6	29
493	Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3368-3375.	0.8	154
494	The genetic landscape of mutations in Burkitt lymphoma. <i>Nature Genetics</i> , 2012, 44, 1321-1325.	9.4	517
495	Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1287-1294.	2.0	31
496	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 725-727.	0.6	3
497	Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. <i>British Journal of Haematology</i> , 2012, 158, 608-614.	1.2	31
498	A Systematic Literature Review and Meta-Analysis of Radioimmunotherapy Consolidation for Patients With Untreated Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 393-399.	0.2	13
499	Considerations in the initial management of follicular lymphoma. <i>Community Oncology</i> , 2012, 9, S53-S60.	0.2	6
500	Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. <i>Community Oncology</i> , 2012, 9, S85-S92.	0.2	6
501	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. <i>Cancer</i> , 2012, 118, 3538-3548.	2.0	19
502	Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States. <i>Cancer</i> , 2012, 118, 4842-4850.	2.0	40
503	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)? A Comparative Survival Analysis using SEER Registry. <i>Blood</i> , 2012, 120, 2072-2072.	0.6	3
504	Racial Disparities in Cell of Origin Among DLBCL Patients.. <i>Blood</i> , 2012, 120, 2686-2686.	0.6	2

#	ARTICLE	IF	CITATIONS
505	Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS). <i>Blood</i> , 2012, 120, 3708-3708.	0.6	4
506	Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3926-3926.	0.6	2
507	Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>European Oncology and Haematology</i> , 2012, 08, 123.	0.0	7
508	Patterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National Lymphocare Study. <i>Blood</i> , 2012, 120, 3702-3702.	0.6	0
509	GM-CSF and IL-4 Derived Fusion Cytokine Reprograms Leukemic B-Cells to Anti-CLL Effectors. <i>Blood</i> , 2012, 120, 4606-4606.	0.6	0
510	Residence Proximity to Benzene Release Sites Is Associated with Increased Incidence of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2012, 120, 2710-2710.	0.6	0
511	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , 2012, 120, 2728-2728.	0.6	2
512	Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 2006-2006.	0.6	0
513	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. <i>Blood</i> , 2012, 120, 898-898.	0.6	0
514	New Challenges in the Management of Diffuse Large B-Cell Lymphoma. <i>Treatment Strategies Hematology</i> , 2012, 2, 68-73.	0.0	2
515	ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. <i>Journal of the American College of Radiology</i> , 2011, 8, 302-308.	0.9	4
516	Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 379-384.	0.2	21
517	Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 498-506.	0.2	62
518	Novel agents for diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 669-680.	1.9	14
519	Correlation of Patient Characteristics Including Age, Obesity, Gender and Race on the Metabolism of Busulfan. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S352-S353.	2.0	0
520	A randomized clinical trial comparing granulocyteâ€“colonyâ€“stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2011, 51, 1779-1783.	0.8	3
521	Effectiveness and cost analysis of â€œjustâ€“inâ€“timeâ€“salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. <i>Transfusion</i> , 2011, 51, 2175-2182.	0.8	93
522	Racial differences in the presentation and outcomes of diffuse large Bâ€“cell lymphoma in the United States. <i>Cancer</i> , 2011, 117, 2530-2540.	2.0	125

#	ARTICLE	IF	CITATIONS
523	Does the Addition of Involved Field Radiotherapy to High-Dose Chemotherapy and Stem Cell Transplantation Improve Outcomes for Patients With Relapsed/Refractory Hodgkin Lymphoma?. International Journal of Radiation Oncology Biology Physics, 2011, 81, 175-180.	0.4	38
524	Idiotypic vaccine strategies for treatment of follicular lymphoma. Future Oncology, 2011, 7, 111-122.	1.1	5
525	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. Journal of Clinical Oncology, 2011, 29, 2787-2794.	0.8	230
526	A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematology, 2011, 2011, 1-14.	1.6	111
527	Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States. Advances in Hematology, 2011, 2011, 1-11.	0.6	90
528	Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. Expert Opinion on Biological Therapy, 2011, 11, 31-40.	1.4	4
529	Patterns of Social Support Among Lymphoma Patients Considering Stem Cell Transplantation. Social Work in Health Care, 2011, 50, 815-827.	0.8	5
530	Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2011, 118, 1628-1628.	0.6	1
531	Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect [®] CLL Disease Registry. Blood, 2011, 118, 2864-2864.	0.6	1
532	Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004-2007. Blood, 2011, 118, 3708-3708.	0.6	24
533	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). Blood, 2011, 118, 3994-3994.	0.6	5
534	Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 4591-4591.	0.6	8
535	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). Blood, 2011, 118, 775-775.	0.6	7
536	A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. Blood, 2011, 118, 97-97.	0.6	10
537	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials. Blood, 2011, 118, 3954-3954.	0.6	0
538	A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL). Blood, 2011, 118, 101-101.	0.6	29
539	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. Blood, 2011, 118, 433-433.	0.6	0
540	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. Blood, 2011, 118, 1959-1959.	0.6	0

#	ARTICLE	IF	CITATIONS
541	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. <i>Blood</i> , 2011, 118, 2988-2988.	0.6	5
542	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 2085-2085.	0.6	3
543	Older Patients with Hodgkin Lymphoma (HL) Undergoing Autologous Stem Cell Transplantation for Relapsed/Refractory Disease Have Inferior Survival Compared to Younger Patients. <i>Blood</i> , 2011, 118, 4521-4521.	0.6	0
544	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. <i>Blood</i> , 2010, 116, 5285-5288.	0.6	25
545	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , 2010, 116, e118-e127.	0.6	188
546	Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 393-408.	157.7	143
547	A black&white comparison of the quality of stage&specific colon cancer treatment. <i>Cancer</i> , 2010, 116, 713-722.	2.0	22
548	ACR Appropriateness Criteria&: Follow-Up of Hodgkin's Lymphoma. <i>Current Problems in Cancer</i> , 2010, 34, 211-227.	1.0	28
549	Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft&versus&host disease. <i>Transfusion</i> , 2010, 50, 2424-2431.	0.8	22
550	A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study. <i>Clinical Cancer Research</i> , 2010, 16, 5079-5086.	3.2	94
551	Surveillance Computed Tomography Scans for Patients With Lymphoma: Is the Risk Worth the Benefits?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 270-277.	0.2	34
552	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.2	43
553	Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. <i>Leukemia and Lymphoma</i> , 2010, 51, 1473-1477.	0.6	77
554	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2010, 116, 803-803.	0.6	0
555	Cost-Effectiveness Analysis of a "Just-In-Time"-Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant. <i>Blood</i> , 2010, 116, 2246-2246.	0.6	1
556	Pharmacokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1359-1359.	0.6	0
557	Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently? Report From the National LymphoCare Study (NLCS). <i>Blood</i> , 2010, 116, 4152-4152.	0.6	0
558	Use of Rituximab with CHOP Chemotherapy Appears to Overcome Racial Disparities In Survival In Black Patients with Diffuse Large B Cell Lymphoma When Compared to CHOP Chemotherapy Alone.. <i>Blood</i> , 2010, 116, 1528-1528.	0.6	16

#	ARTICLE	IF	CITATIONS
559	Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS). <i>Blood</i> , 2010, 116, 1768-1768.	0.6	2
560	Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2010, 116, 1521-1521.	0.6	0
561	Improving our use and understanding of antibodies in B-cell lymphomas. <i>Oncology</i> , 2010, 24, 176-7.	0.4	4
562	Development of the Lymphoma Enterprise Architecture Database: A caBIG ^{â„¢} Silver Level Compliant System. <i>Cancer Informatics</i> , 2009, 8, CIN.S940.	0.9	18
563	Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5023-5030.	0.8	96
564	Examining Racial Disparities in Colorectal Cancer Care. <i>Journal of Psychosocial Oncology</i> , 2009, 27, 59-83.	0.6	81
565	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	0.8	263
566	Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. <i>BMC Health Services Research</i> , 2009, 9, 9.	0.9	81
567	Extracorporeal Photopheresis Therapy For Chronic Graft-Versus-Host Disease: Response Is Associated With Content Of Dendritic Cells And T-Cells In Peripheral Blood At Initiation Of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 128-129.	2.0	9
568	Pharmacokinetic (PK) Comparison Of Intravenous Versus Oral Busulfan Conditioning Regimens for Acute Myeloid Leukemia (AML) And Myelodysplastic Syndrome (MDS) Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 154-155.	2.0	18
569	A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 49-55.	0.6	28
570	Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks. <i>Epidemiology and Infection</i> , 2009, 137, 1323-1332.	1.0	14
571	Prescription Opioid Usage and Abuse Relationships: An Evaluation of State Prescription Drug Monitoring Program Efficacy. <i>Substance Abuse: Research and Treatment</i> , 2009, 3, SART.S2345.	0.5	67
572	Black/White Differences in the Treatment and Outcomes of Diffuse Large B Cell Lymphoma: A Matched Cohort Analysis.. <i>Blood</i> , 2009, 114, 1392-1392.	0.6	4
573	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. <i>Blood</i> , 2009, 114, 1689-1689.	0.6	6
574	Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2009, 114, 2947-2947.	0.6	2
575	The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated.. <i>Blood</i> , 2009, 114, 3718-3718.	0.6	6
576	Disparities in the Use of Chemo-Immunotherapy for Diffuse Large B-Cell Lymphoma in the United States.. <i>Blood</i> , 2009, 114, 897-897.	0.6	4

#	ARTICLE	IF	CITATIONS
577	Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS).. <i>Blood</i> , 2009, 114, 1381-1381.	0.6	0
578	Racial Differences in the Presentation and Outcomes of Diffuse Large B-Cell Lymphoma in the United States.. <i>Blood</i> , 2009, 114, 898-898.	0.6	2
579	A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.. <i>Blood</i> , 2009, 114, 2403-2403.	0.6	0
580	Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 529-534.	1.3	16
581	Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. <i>Leukemia and Lymphoma</i> , 2008, 49, 2099-2107.	0.6	136
582	Idiotype vaccine strategies for improving outcomes in follicular lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1213-1223.	1.4	3
583	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2008, 112, 3332-3332.	0.6	2
584	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. <i>Blood</i> , 2008, 112, 3644-3644.	0.6	0
585	Lymphoma and Whole Body CT Scan Mortality Risk. <i>Blood</i> , 2008, 112, 1321-1321.	0.6	0
586	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 1183-1183.	0.6	0
587	Examining Decision Making Styles in Patients with Sickle Cell Disease (SCD) Regarding Allogeneic Stem Cell Transplantation (ASCT). <i>Blood</i> , 2008, 112, 168-168.	0.6	0
588	American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2007, 3, 326-329.	2.5	5
589	BiovaxIDâ„¢ idiotype vaccination: active immunotherapy for follicular lymphoma. <i>Expert Review of Vaccines</i> , 2007, 6, 307-317.	2.0	12
590	Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 116-123.	2.0	87
591	150: A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 56.	2.0	74
592	Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantationâ€”A Similar Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 746-747.	2.0	8
593	Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 895-904.	2.0	16
594	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505.	0.8	875

#	ARTICLE	IF	CITATIONS
595	Maintenance Therapy in Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 507-513.	1.4	22
596	Development of Query Strategies to Identify a Histologic Lymphoma Subtype in a Large Linked Database System. <i>Cancer Informatics</i> , 2007, 3, 117693510700300.	0.9	5
597	Racial Differences in the Incidence and Outcomes for Patients with Hematological Malignancies. <i>Current Problems in Cancer</i> , 2007, 31, 182-201.	1.0	26
598	In reply to Drs. Nieder and Andratschke. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1278.	0.4	0
599	Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy. <i>Value in Health</i> , 2007, 10, 23-31.	0.1	40
600	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , 2007, 47, 629-635.	0.8	19
601	Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 3111-3111.	0.6	4
602	Response and Survival Rates in Patients with Peripheral T-Cell Lymphoma Treated with Anthracycline-Based Regimens: A Comprehensive Meta-Analysis.. <i>Blood</i> , 2007, 110, 3452-3452.	0.6	15
603	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2007, 110, 949-949.	0.6	3
604	Therapeutic Drug Monitoring (TDM) of IV Busulfan in Patients with Severe Obesity.. <i>Blood</i> , 2007, 110, 1990-1990.	0.6	0
605	Examining Decision Making Styles in Patients with Lymphoma and Multiple Myeloma Considering Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 3322-3322.	0.6	0
606	The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.. <i>Blood</i> , 2007, 110, 1912-1912.	0.6	0
607	Racial variation in colorectal polyp and tumor location. <i>Journal of the National Medical Association</i> , 2007, 99, 723-8.	0.6	66
608	Development of query strategies to identify a histologic lymphoma subtype in a large linked database system. <i>Cancer Informatics</i> , 2007, 3, 149-58.	0.9	6
609	Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2155-2162.	0.6	11
610	Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Clinical Leukemia</i> , 2006, 1, 46-56.	0.2	0
611	Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 69-70.	2.0	1
612	Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 132.	2.0	1

#	ARTICLE	IF	CITATIONS
613	Value of PET restaging after chemotherapy for non-Hodgkinâ€™s lymphoma: Implications for consolidation radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 961-965.	0.4	24
614	T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT).. Blood, 2006, 108, 3224-3224.	0.6	1
615	Determining the Benefits of Rituximab + Chemotherapy for Patients with Untreated Follicular Lymphoma: A Comprehensive Meta-Analysis.. Blood, 2006, 108, 3330-3330.	0.6	1
616	Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.. Blood, 2006, 108, 694-694.	0.6	8
617	Infliximab for the Treatment of Chronic Graft Versus Host Disease.. Blood, 2006, 108, 2889-2889.	0.6	0
618	Mechanism for the Immuno-Suppression Activity of Pentostatin: Selective Apoptosis of Naive T Cell Subsets.. Blood, 2006, 108, 5160-5160.	0.6	0
619	Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.. Blood, 2006, 108, 1960-1960.	0.6	0
620	Patients Receiving Palifermin in Conjunction with Melphalan 200 Required Fewer Platelet Transfusions: Analysis of a Retrospective Cohort Study.. Blood, 2006, 108, 5261-5261.	0.6	0
621	Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.. Blood, 2006, 108, 4989-4989.	0.6	0
622	Benefits of CHOP-14 Followed by Transplantation in Patients with Peripheral T-Cell Lymphoma.. Blood, 2006, 108, 4689-4689.	0.6	0
623	A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.. Blood, 2006, 108, 3377-3377.	0.6	1
624	Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.. Blood, 2006, 108, 3065-3065.	0.6	0
625	Refractory or Relapsed Hodgkin's Disease and Non-Hodgkin's Lymphoma. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rrgBT /Ov 1.0 11		
626	Prophylactic Cholecystectomy in Transplant Patients: A Decision Analysis. Journal of Gastrointestinal Surgery, 2005, 9, 965-972.	0.9	42
627	Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 153-162.	0.7	61
628	Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkinâ€™s Lymphoma (NHL): A Phase 2 Study.. Blood, 2005, 106, 17-17.	0.6	14
629	Systematic Review and Meta-Analysis of Radioimmunotherapy Regimens in Patients with Relapsed Follicular and Transformed Nonhodgkins Lymphomas.. Blood, 2005, 106, 3113-3113.	0.6	1
630	Patient Characteristics in CD 20+ and CD 20~ Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.. Blood, 2005, 106, 4523-4523.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Ex Vivo Fludarabine Selectively Depletes Human Naive T-Cell Subsets: A Step Toward Modifying Donor Lymphocyte Infusion.. Blood, 2005, 106, 1071-1071.	0.6	0
632	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. Blood, 2005, 106, 4634-4634.	0.6	0
633	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. Blood, 2005, 106, 2016-2016.	0.6	0
634	Determining the Benefits of Chemotherapy for Achieving Complete Response in Patients with Untreated Advanced Stage Follicular Lymphoma: A Systematic Review and Meta-Analysis.. Blood, 2005, 106, 290-290.	0.6	1
635	A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.. Blood, 2005, 106, 1960-1960.	0.6	0
636	The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics. Pharmacoeconomics, 2004, 22, 481-493.	1.7	97
637	Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood, 2004, 104, 961-968.	0.6	300
638	Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood, 2004, 104, 1550-1558.	0.6	299
639	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.. Blood, 2004, 104, 1814-1814.	0.6	2
640	A Randomized Trial to Evaluate the Impact of Cytokines on Dendritic Cell, T-Cell and T-Cell Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant: An Interim Analysis.. Blood, 2004, 104, 2854-2854.	0.6	0
641	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. Blood, 2004, 104, 3159-3159.	0.6	0
642	A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. Journal of the American College of Surgeons, 2003, 196, 385-393.	0.2	118
643	Comparing the Cost-Effectiveness of the Triple Test Score to Traditional Methods for Evaluating Palpable Breast Masses. Medical Care, 2003, 41, 962-971.	1.1	9
644	Nonmyeloablative Hematopoietic Cell Transplantation. Annals of the New York Academy of Sciences, 2001, 938, 328-339.	1.8	65
645	Clinical investigators as critical determinants in pharmaceutical innovation. Nature Medicine, 1997, 3, 136-143.	15.2	36
646	Cyclosporin and the clinical investigator. Nature Medicine, 1997, 3, 590-590.	15.2	0
647	Aesthetic preference and DSM-III-R personality disorders. Personality and Individual Differences, 1995, 18, 797-799.	1.6	4